Autolus Therapeutics plc (AUTL) |
|
1.82 -0.05 (-2.67%)
|
03-24 16:00 |
|
Open: |
1.84 |
Pre. Close: |
1.87 |
|
High:
|
1.85 |
Low:
|
1.74 |
|
Volume:
|
295,563 |
Market Cap:
|
315(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:24:11 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 2.32  One year: 2.51 |
| Support: |
Support1: 1.74 Support2: 1.44 |
| Resistance: |
Resistance1: 1.99 Resistance2: 2.15 |
| Pivot: |
1.99 |
| Moving Average: |
MA(5): 1.93 MA(20): 1.96
MA(100): 2.1 MA(250): 2.64 |
| MACD: |
MACD(12,26): -0.1 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 20.1 %D(3): 38 |
| RSI: |
RSI(14): 40.1 |
| 52-week: |
High: 4.73 Low: 1.6 |
| Average Vol(K): |
3-Month: 564 (K) 10-Days: 482 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AUTL ] has closed above bottom band by 6.8%. Bollinger Bands are 49.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 57 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.85 - 1.86 |
1.86 - 1.87 |
|
Low:
|
1.72 - 1.73 |
1.73 - 1.74 |
|
Close:
|
1.8 - 1.82 |
1.82 - 1.84 |
|
Company Description |
|
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom. |
Headline News |
Sat, 18 Mar 2023
Bryan, Garnier & Co Begins Coverage on Autolus Therapeutics ... - MarketBeat
Mon, 13 Mar 2023
Analysts Offer Predictions for Autolus Therapeutics plc's Q1 2023 ... - MarketBeat
Wed, 08 Mar 2023
Tesla To Rally More Than 12%? Here Are 10 Other Analyst ... - Benzinga
Wed, 08 Mar 2023
Autolus Therapeutics plc (NASDAQ:AUTL) Q4 2022 Earnings Call Transcript - Yahoo Finance
Wed, 01 Mar 2023
11 High Growth UK Stocks to Buy - Yahoo Finance
Tue, 14 Feb 2023
Autolus Therapeutics: The Story Has Improved (NASDAQ:AUTL) - Seeking Alpha
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
-91 (M) |
| Shares Float |
0 (M) |
|
% Held by Insiders
|
1.7308e+008 (%) |
|
% Held by Institutions
|
5.705e+007 (%) |
|
Shares Short
|
0 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-811000 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
-1.62 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-2 |
|
Return on Assets (ttm)
|
634.1 |
|
Return on Equity (ttm)
|
-23.4 |
|
Qtrly Rev. Growth
|
6.36e+006 |
|
Gross Profit (p.s.)
|
572.02 |
|
Sales Per Share
|
-51.01 |
|
EBITDA (p.s.)
|
-8.38354e+007 |
|
Qtrly Earnings Growth
|
-1.6017e+008 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
-1.14 |
|
Price to Sales
|
-0.04 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
1.13e+006 |
|
Forward Dividend
|
877410 |
|
Dividend Yield
|
62087900% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
